LONDON, UK / ACCESSWIRE / January 31, 2018 / Active-Investors.com has just released a free research report on Melinta Therapeutics, Inc. (NASDAQ: MLNT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MLNT as the Company’s latest news hit the wire. On January 29, 2018, the Company announced that it has launched intravenous and oral formulations of Baxdela™ (delafloxacin) in the United States for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. Baxdela™ does not require dosage adjustments due to weight, hepatic impairment, or mild-moderate renal impairment, there are no food effects, and there is minimal potential for drug interactions. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Melinta Therapeutics most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=MLNT
Melinta Will Market Baxdela™ Leveraging an Industry-Leading Commercial Sales Team
The Company plans to market Baxdela™ nationwide leveraging an industry-leading commercial sales team. Baxdela™ joins a strong portfolio of infectious disease products that will be marketed by Melinta, including Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for injection.
Launch is Enhanced by Availability of Three Antimicrobial Susceptibility Tests
Mike McGuire, Senior Vice President of Melinta Commercial, stated that Baxdela™ will be an important treatment option for providers treating serious skin infections in both the hospital and community settings. These patients often present treatment challenges owing to their underlying medical conditions, which makes optimal antibiotic selection difficult. Mike added that the launch has the support of an experienced sales team and is further enhanced by the availability of three antimicrobial susceptibility tests that offer providers a full set of clinical tools to determine how to treat patients appropriately.
FDA Cleared ASTs Concurrent with Baxdela™ Launch in the US
In October 2017, the US Food and Drug Administration (FDA) cleared three antimicrobial susceptibility tests (ASTs) that would be available to guide physicians towards the appropriate usage of Baxdela™. The three ASTs that were cleared are: Hardy Diagnostics’ Delafloxacin Antimicrobial Susceptibility Disk (HardyDisk™), Liofilchem® Delafloxacin MIC Test Strip (MTS), and Thermo Scientific™ Sensititre™ MIC System. ASTs are used to determine how well specific antibiotics work against bacterial pathogens and they are vital for physicians to understand the appropriate use of an antibiotic.
FDA approved Baxdela™ for the treatment of ABSSSI in adults caused by susceptible bacteria, on June 19, 2017. The Baxdela™ New Drug Application (NDA) approvals were supported by two Phase-3 studies in patients with ABSSSI, demonstrating in-vitro and clinical activity against Gram-positive and Gram-negative pathogens, including activity against MRSA (methicillin-resistant Staphylococcus aureus).
What is Acute Bacterial Skin and Skin Structure Infections?
A skin and skin structure infection (SSSI), also referred to as acute bacterial skin and skin structure infection (ABSSSI), is an infection of skin and associated soft tissues (such as loose connective tissue and mucous membranes). The pathogen involved is usually a bacterial species. Such infections often require treatment by antibiotics. ABSSSI includes infections with resistance to previously effective antimicrobials.
About Baxdela™
Baxdela™ (Delafloxacin)is an anionic fluoroquinolone antibiotic, a class currently used in one out of three hospital-treated infections. It was given priority review by the FDA due to its designation as a Qualified Infectious Disease Product (QIDP) under the Generating Antibiotic Incentives Now (GAIN) Act of 2012. Baxdela™ provides for convenient administration with both intravenous and oral forms. The most common adverse reactions in patients treated with Baxdela were nausea, diarrhea, headache, transaminase elevations and vomiting. A FDA-approved patient labeling guide is available for patients taking Baxdela™.
About Melinta Therapeutics, Inc.
Founded in 2000, Melinta Therapeutics is a commercial-stage biopharmaceutical company dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. The Company is headquartered in New Haven, Connecticut.
Stock Performance Snapshot
January 30, 2018 – At Tuesday’s closing bell, Melinta Therapeutics’ stock dropped 3.01%, ending the trading session at $14.50.
Volume traded for the day: 76.71 thousand shares.
Stock performance in the previous three-month period – up 36.47%
After yesterday’s close, Melinta Therapeutics’ market cap was at $468.35 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
ReleaseID: 487432
